Be SMART NIS, Moderate to Servere Asthma Patient Observation

Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia

NCT00939341 ·Status: COMPLETED ·Phase: PHASE4

Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy

NCT03629782 ·Status: COMPLETED

Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients

NCT01327001 ·Status: COMPLETED

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

NCT00455923 ·Status: COMPLETED ·Phase: PHASE4

Observational Study Regarding Adherence, Drug Use, Will to Take Part in Shared Decisioning in Asthma Outpatients

NCT00557141 ·Status: UNKNOWN

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

NCT00573222 ·Status: COMPLETED

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

NCT01647646 ·Status: COMPLETED ·Phase: PHASE4

Local Phase 4 Pan-European SMART Study

NCT00463866 ·Status: COMPLETED ·Phase: PHASE4

Characteristics of Pts Initiating Spiriva Respimat in Asthma

NCT03692676 ·Status: COMPLETED

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

NCT01641692 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)

NCT00882128 ·Status: COMPLETED

NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler

NCT00557297 ·Status: COMPLETED

Symbicort SMART (Symbicort Maintenance And Reliever Therapy)

NCT00523679 ·Status: COMPLETED

Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice

NCT00782314 ·Status: COMPLETED

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

NCT00479739 ·Status: COMPLETED ·Phase: PHASE4

The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics

NCT00453791 ·Status: TERMINATED ·Phase: PHASE1

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

NCT00358488 ·Status: COMPLETED ·Phase: PHASE2

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

NCT01245426 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics

NCT00857857 ·Status: COMPLETED ·Phase: PHASE2

Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting

NCT06678191 ·Status: RECRUITING

A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

NCT00505388 ·Status: COMPLETED

Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma

NCT01078688 ·Status: COMPLETED

A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma

NCT02182661 ·Status: COMPLETED ·Phase: PHASE3

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

NCT00784953 ·Status: COMPLETED

A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

NCT00503061 ·Status: COMPLETED